Regeneron Pharmaceuticals Statistics

Total Valuation

LON:0R2M has a market cap or net worth of GBP 46.04 billion. The enterprise value is 34.75 billion.

Market Cap	46.04B
Enterprise Value	34.75B

Important Dates

The last earnings date was Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	May 20, 2025

Share Statistics

Current Share Class	103.85M
Shares Outstanding	n/a
Shares Change (YoY)	+0.13%
Shares Change (QoQ)	-2.28%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	101.65M

Valuation Ratios

The trailing PE ratio is 13.22 and the forward PE ratio is 15.01.

PE Ratio	13.22
Forward PE	15.01
PS Ratio	4.22
PB Ratio	2.02
P/TBV Ratio	2.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.18, with an EV/FCF ratio of 14.47.

EV / Earnings	9.98
EV / Sales	3.26
EV / EBITDA	10.18
EV / EBIT	11.55
EV / FCF	14.47

Financial Position

The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.09.

Current Ratio	4.93
Quick Ratio	3.90
Debt / Equity	0.09
Debt / EBITDA	0.60
Debt / FCF	0.87
Interest Coverage	83.17

Financial Efficiency

Return on equity (ROE) is 15.96% and return on invested capital (ROIC) is 8.04%.

Return on Equity (ROE)	15.96%
Return on Assets (ROA)	6.91%
Return on Invested Capital (ROIC)	8.04%
Return on Capital Employed (ROCE)	11.70%
Revenue Per Employee	719,237
Profits Per Employee	229,741
Employee Count	15,106
Asset Turnover	0.39
Inventory Turnover	2.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.70% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-44.70%
50-Day Moving Average	620.58
200-Day Moving Average	827.67
Relative Strength Index (RSI)	45.96
Average Volume (20 Days)	555

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.61

Income Statement

In the last 12 months, LON:0R2M had revenue of GBP 10.90 billion and earned 3.48 billion in profits. Earnings per share was 30.52.

Revenue	10.90B
Gross Profit	5.32B
Operating Income	3.08B
Pretax Income	3.86B
Net Income	3.48B
EBITDA	3.46B
EBIT	3.08B
Earnings Per Share (EPS)	30.52

Full Income Statement

Balance Sheet

The company has 6.46 billion in cash and 2.09 billion in debt, giving a net cash position of 11.55 billion.

Cash & Cash Equivalents	6.46B
Total Debt	2.09B
Net Cash	11.55B
Net Cash Per Share	n/a
Equity (Book Value)	22.75B
Book Value Per Share	214.78
Working Capital	10.84B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.06 billion and capital expenditures -658.90 million, giving a free cash flow of 2.40 billion.

Operating Cash Flow	3.06B
Capital Expenditures	-658.90M
Free Cash Flow	2.40B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 48.80%, with operating and profit margins of 28.22% and 31.94%.

Gross Margin	48.80%
Operating Margin	28.22%
Pretax Margin	35.38%
Profit Margin	31.94%
EBITDA Margin	31.74%
EBIT Margin	28.22%
FCF Margin	22.02%

Dividends & Yields

This stock pays an annual dividend of 0.70, which amounts to a dividend yield of 0.12%.

Dividend Per Share	0.70
Dividend Yield	0.12%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	2.08%
Buyback Yield	-0.13%
Shareholder Yield	-0.01%
Earnings Yield	7.56%
FCF Yield	5.21%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0R2M has an Altman Z-Score of 9.55.

Altman Z-Score	9.55
Piotroski F-Score	n/a